Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Table 3 Unit costs for model treatments

Drug acquisition costs	Dosing and frequency	Unit cost, GBP
¹⁷⁷Lu-Dotatate 7.4 GBq (200 mCi) (Lutathera)	4 administrations of 7.4 GBq (200 mCi), administered once every 8 weeks	71,500 (for 4 administrations)
Octreotide LAR	60 mg/ 30 mg administered once every 28 days	1 × 30 mg vial, 998.41
Everolimus (Afinitor)	10 mg administered once daily	1 × 30 tab pack (10 mg), 2673
Sunitinib (Sutent)	37.5 mg administered once daily	1 × 30 tab pack (12.5 mg), 784.70

Costs of medications administered prior to or concomitantly with ¹⁷⁷Lu-Dotatate (i.e. anti-emetics and amino acids) were also included in the analysis with data on doses and frequency of administration sourced from clinical trials

ISSN: 1471-2407